- Home
- RNA vs AB Comparison
RNA vs AB Comparison
Compare RNA & AB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNA
- AB
- Stock Information
- Founded
- RNA 2012
- AB 1987
- Country
- RNA United States
- AB United States
- Employees
- RNA N/A
- AB N/A
- Industry
- RNA Biotechnology: Pharmaceutical Preparations
- AB Investment Managers
- Sector
- RNA Health Care
- AB Finance
- Exchange
- RNA Nasdaq
- AB Nasdaq
- Market Cap
- RNA 4.0B
- AB 4.5B
- IPO Year
- RNA 2020
- AB 1988
- Fundamental
- Price
- RNA $41.81
- AB $38.81
- Analyst Decision
- RNA Strong Buy
- AB Hold
- Analyst Count
- RNA 16
- AB 5
- Target Price
- RNA $69.81
- AB $39.60
- AVG Volume (30 Days)
- RNA 3.7M
- AB 164.1K
- Earning Date
- RNA 11-06-2025
- AB 10-23-2025
- Dividend Yield
- RNA N/A
- AB 8.39%
- EPS Growth
- RNA N/A
- AB 17.05
- EPS
- RNA N/A
- AB 3.37
- Revenue
- RNA $10,729,000.00
- AB N/A
- Revenue This Year
- RNA N/A
- AB N/A
- Revenue Next Year
- RNA $109.60
- AB $9.45
- P/E Ratio
- RNA N/A
- AB $11.54
- Revenue Growth
- RNA 1.23
- AB N/A
- 52 Week Low
- RNA $21.51
- AB $32.28
- 52 Week High
- RNA $56.00
- AB $43.30
- Technical
- Relative Strength Index (RSI)
- RNA 45.80
- AB 46.06
- Support Level
- RNA $39.83
- AB $37.80
- Resistance Level
- RNA $42.42
- AB $38.53
- Average True Range (ATR)
- RNA 2.92
- AB 0.63
- MACD
- RNA -1.12
- AB 0.01
- Stochastic Oscillator
- RNA 38.92
- AB 54.91
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
About AB AllianceBernstein Holding L.P.
AllianceBernstein provides investment management services to institutional (41% of assets under management), retail (42%), and private (17%) clients through products that includes mutual funds, hedge funds, and separately managed accounts. At the end of June 2025, the company had $829 billion in managed assets, composed primarily of fixed-income (37% of AUM) and equity (41%) strategies, with other investments (made up of asset allocation services and certain other alternative investments) accounting for the remainder.